Hôpital Européen Georges Pompidou
Paris, 75015, France
Location status: Recruiting
Location contact
Nicolas BRECHOT, MD, PhD
CONTACT
Nicolas BRECHOT, MD, PhD
CONTACT
NCT Number: NCT05586282
* Testing the association between circulating candidate proteins and the level of vascular leakage for three distinct forms of circulatory failure: cardiogenic shock, septic shock, and post-resuscitation syndrome. * Describing immuno-inflammatory profiles associated with massive vascular leakage during those three forms of circulatory failure in humans
Interested in participating?
Request Info18 year and older
All sexes
Observational
Paris, 75015, France
Location status: Recruiting
Nicolas BRECHOT, MD, PhD
CONTACT
Nicolas BRECHOT, MD, PhD
CONTACT
Circulatory shocks are responsible for one third of intensive care unit (ICU) admissions (20,000 patients per year in France) and are associated with 40% mortality [1,2]. Vascular hyperpermeability (also called vascular leakage) is a major feature of circulatory failure. During systemic inflammatory response syndrome (SIRS), massive vascular leakage affects macro and micro-circulation, and participates in the development of multiple organ failure [1,3]. Accordingly, fluid balance (the difference between fluid input and output) correlates independently with mortality during both septic and cardiogenic shock [4-7] and controlling capillary leakage was highly beneficial in numerous animal models of circulatory failure [8-10]. However, the determinants of vascular leakage remain poorly understood in humans.
The purpose of this study is to evaluate the link between circulatory levels of several proteins and the level of vascular leakage, in three distinct types of circulatory shocks.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Between Day 0 and Day 3
(ml/kg of initial body weight). The fluid balance, routinely monitored in ICU, represents fluid intakes (perfusion, oral intakes,..) - fluid losses (diuresis, diarrhea,…)
Time frame: Day 1, Day 3, Day 7, Day 14
(ml/kg of initial body weight). The fluid balance, routinely monitored in ICU, represents fluid intakes (perfusion, oral intakes,..) - fluid losses (diuresis, diarrhea,…)
Time frame: Day 0, Day 1, Day 3, Day 7, Day 14
Extra-vascular lung water index (EVLWi, ml/kg) and pulmonary vascular permeability index measured by transpulmonary thermodilution at corresponding time-points
Time frame: Day 0, Day 1, Day 3, Day 7, Day 14
g/L
Time frame: Day 0, Day 1, Day 3, Day 7, Day 14
mmoles/L
Time frame: Day 0, Day 1, Day 3, Day 7, Day 14
(mmHg)
Time frame: Day 0, Day 1, Day 3, Day 7, Day 14
(pg/ml)
Time frame: Day 0, Day 1, Day 3, Day 7, Day 14
(pg/ml)
Time frame: Day 0, Day 1, Day 3, Day 7, Day 14
(pg/ml)
Time frame: Day 0, Day 1, Day 3, Day 7, Day 14
(pg/ml)
Time frame: Day 0, Day 1, Day 3, Day 7, Day 14
Association between circulating candidate proteins, the immune-inflammatory profile of the patients and SOFA score
Time frame: Day 0 to Day 7, Day 30
Number of days alive without receiving any catecholamine
Time frame: Day 0 to Day 7, Day 30
Number of days alive without receiving any machenical ventilation, invasive or non-invasive
Time frame: Day 0 to Day 7, Day 30
Number of days alive without receiving any renal replacement therapy
Time frame: Day 30
Contact information is provided by the study sponsor or research team.
Assistance Publique - Hôpitaux de Paris
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05146336
Acute Liver Failure, Acute Respiratory Distress Syndrome
Klagenfurt, Austria
View Trial DetailsNCT07184593
Acute Brain Injury, Brain Diseases
View Trial DetailsNCT04901338
ARDS, Human, Cardiac Arrest
Ljubljana, Slovenia
View Trial DetailsNCT02558166
Acute Kidney Injury, Cardiogenic Shock
Amsterdam, North Holland, Netherlands
View Trial Details